Biocon opens first U.S. manufacturing facility in New Jersey

Biocon Limited has officially opened its first U.S. manufacturing facility in Cranbury, New Jersey, through its wholly owned subsidiary, Biocon Generics Inc (BGI). The inauguration on September 10, 2025, was attended by New Jersey governor Phil Murphy and Biocon's chairperson, Kiran Mazumdar-Shaw. This strategic move aims to enhance access to essential therapies and strengthen the company's supply chain in the U.S.

The company acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over $30 million. This investment has transformed the site into a state-of-the-art plant capable of producing 2 bn tablets annually. Several products are already commercialized from this facility, with more in the pipeline, diversifying Biocon's manufacturing base and accelerating its global expansion.

According to Kiran Mazumdar-Shaw, this FDA-approved facility marks a new chapter in Biocon's global expansion, reaffirming its commitment to serving patients worldwide and strengthening the U.S. healthcare ecosystem. Siddharth Mittal, chief executive and managing director of Biocon Ltd, emphasized that this investment brings the company closer to patients, healthcare providers, and partners, ensuring more efficient delivery of high-quality medicines.